FDA backs pediatric warnings on Zyprexa, Lamisil

In advance of tomorrow's pediatric advisory committee meeting at the FDA, agency staffers are recommending new cautionary language for Eli Lilly's antipsychotic Zyprexa (about the risks of weight gain and diabetes in children) and Novartis' antifungal Lamisil (about the risk of psychiatric side effects, also in children). Report